Previous Article | Next Article 
Infection and Immunity, September 1999, p. 4383-4392, Vol. 67, No. 9
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Protective Role for Interleukin-5 during
Chronic Toxoplasma gondii Infection
Yin
Zhang and
Eric Y.
Denkers*
Department of Microbiology and Immunology,
College of Veterinary Medicine, Cornell University, Ithaca, New
York 14853
Received 5 March 1999/Returned for modification 29 April
1999/Accepted 7 June 1999
 |
ABSTRACT |
To investigate the role of interleukin-5 (IL-5) during
Toxoplasma gondii infection, IL-5 knockout (KO) mice and
C57BL/6 control mice were infected intraperitoneally with ME49 cysts
and the course of infection was monitored. The mortality rate during
chronic infection was significantly greater in IL-5-deficient animals, and consistent with this finding, the KO mice harbored a greater number
of brain cysts and tachyzoites than did their wild-type counterparts.
Although the IL-5 KO animals did not succumb until late during
infection, increased susceptibility, as measured by accelerated weight
loss, was detectable during the acute stages of infection. The amounts
of total immunoglobulin (Ig), IgM, and IgG2b were comparable in both
strains, while the amount of IgG1 was much smaller in IL-5 KO mice.
Spleen cell production of IL-12 in response to T. gondii
antigen was approximately threefold lower in the KO strain, and this
decrease correlated with a selective loss of B lymphocytes during
culture. A link between the presence of B cells and augmented IL-12
production was established by the finding that after removal of B cells
with monoclonal antibody and complement, wild-type- and KO-derived
cells produced equivalent levels of IL-12 in response to T. gondii antigen. These results demonstrate a protective role of
IL-5 against T. gondii infection and suggest that IL-5 may
play a role in the production of IL-12.
 |
INTRODUCTION |
The intracellular protozoan parasite
Toxoplasma gondii is a frequently occurring opportunistic
pathogen among humans and animals. Infection is characterized by an
acute phase and a chronic phase. During acute infection, the tachyzoite
form of the parasite replicates intracellularly, rapidly leading to
host cell lysis. The released tachyzoites then infect new cells. With
the rise of the parasite-specific immune response, tachyzoites are
cleared and a chronic phase of infection follows, in which the parasite
encysts in the form of long-lived bradyzoites. The cysts are found
predominantly within the central nervous system, where they cause
little inflammation (28). Nevertheless, intact immune system
defenses are required during this stage of infection, as evidenced by
the occurrence of toxoplasmic encephalitis in AIDS patients and in
experimental models of immunosuppression (29, 32).
It is well established that T. gondii infection induces a
strong cell-mediated immune response. Type 1 cytokines such as gamma interferon (IFN-
), interleukin-12 (IL-12), and tumor necrosis factor
alpha (TNF-
) are crucial in protective immunity. The absence of any
one of these proinflammatory mediators results in increased mortality
as a result of uncontrolled tachyzoite growth (1, 10, 13,
43). It is also clear that type 2 cytokine responses play an
important role during T. gondii infection. Thus, infection of IL-4 knockout (KO) mice with T. gondii ME49 leads to
increased susceptibility associated with severe inflammation in the
central nervous system during chronic toxoplasmosis (48). In
addition, infection of IL-10 KO animals results in early death of the
mice in association with abnormally high levels of inflammatory
cytokines (15, 35).
The type 2 cytokine IL-5 is a homodimeric glycoprotein produced
predominantly by activated CD4+ T cells (22).
The cytokine has several effects on B lymphocytes. Thus, IL-5 enhances
B-cell IL-2 receptor expression and promotes B-cell proliferation and
differentiation (49, 51, 52). The cytokine also enhances
immunoglobulin A (IgA) production by lipopolysaccharide-stimulated B
cells (49) and works with IL-4 to promote IgG1 production (30). Recent studies with IL-5 KO mice have revealed a
requirement for this cytokine in B-1-cell development (26).
IL-5 is also essential for production and function of eosinophils and
serves as an antiapoptotic factor for the latter cells (47).
Although none of the known functions of IL-5 would be predicted to be
required to survive T. gondii infection, it has been shown
that this type 2 cytokine is induced in the brain, spleen, and
mesenteric lymph nodes during the normal course of murine infection
(2, 6). The recent construction of IL-5 KO mice allowed us
to evaluate host responses to T. gondii infection in the
absence of this cytokine. Surprisingly, IL-5 KO animals displayed increased cyst and tachyzoite burdens and accelerated mortality during
chronic infection. Splenocytes from infected IL-5 KO mice produced less
IL-12 when restimulated with parasite antigen, and this impairment was
associated with selective B-cell loss during culture. Our data uncover
a previously unknown function for IL-5 as a cytokine which promotes
IL-12 production.
 |
MATERIALS AND METHODS |
Mice.
Swiss-Webster and C57BL/6 mice were obtained from the
Taconic Farms Inc. (Germantown, N.Y.). Female RAG-1 KO and matched
wild-type (WT) mice were obtained from The Jackson Laboratory (Bar
Harbor, Maine). IL-5
/
animals (C57BL/6 background),
originally provided by M. Kopf (Basel Institute for Immunology, Basel,
Switzerland), were bred and maintained in the College of Veterinary
Medicine animal facility at Cornell University. The animals were housed
under specific-pathogen-free conditions and were used at 6 to 8 weeks
of age. The experiments used both male and female mice as specified.
Parasites and antigen.
The cystogenic T. gondii
strain, ME49, was maintained by serial passage in female Swiss-Webster
mice. Briefly, the animals were infected by intraperitoneal (i.p.)
inoculation of 20 ME49 cysts, and 4 to 6 weeks later their brains were
removed and homogenized in phosphate-buffered saline (PBS). The cysts
were enumerated and either used immediately for experiments or injected
i.p. into new Swiss-Webster mice. The virulent parasite strain, RH, was maintained in vitro by twice-weekly passage on human foreskin fibroblasts in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Gaithersburg, Md.) supplemented with 1% fetal calf serum
(HyClone Laboratories, Logan, Utah), penicillin (100 U/ml), and
streptomycin (100 µg/ml) (both from Life Technologies). Soluble tachyzoite antigen (STAg) was prepared by sonication of RH strain tachyzoites in the presence of protease inhibitors followed by centrifugation at 10,000 × g and dialysis against PBS
as described elsewhere (31).
RT-PCR and Southern blot analysis.
Reverse transcription-PCR
(RT-PCR) was carried out essentially as described elsewhere
(57) but with minor modifications. To obtain brain and
spleen RNA, these organs were removed and homogenized in 2 ml of PBS
(brain) or DMEM (spleen), and then 300 µl of homogenate was
centrifuged at 1,000 × g for 7 min at 4°C,
resuspended in 1 ml of RNA STAT-60 (Tel-Test, Inc., Friendswood, Tex.),
and either snap frozen in a mixture of dry ice and methanol or used
immediately for cDNA synthesis. RNA was purified by following the
protocols provided by the company. Briefly, 100 µl of chloroform was
added to the samples and the mixture was vigorously shaken for 5 min.
The samples were incubated for 15 min at room temperature and then
centrifuged for 15 min at 13,000 × g and 4°C. The
upper, aqueous phase was transferred to a fresh tube, an equal volume of isopropanol was added, and RNA was allowed to precipitate by overnight incubation at
20°C. RNA was pelleted by centrifugation for 15 min at 1,300 × g and 4°C, washed in 95%
ethanol, air dried, and resuspended in H2O. The optical
density at 260 nm was measured in a spectrophotometer equipped with a
UV lamp (DU-50; Beckman Instruments, Inc., Irvine, Calif.) to estimate
the RNA concentration.
The RNA samples (10 µg) were reverse transcribed into cDNA in a
25-µl reaction volume containing 200 U of reverse transcriptase, 20 U
of RNasin, 40 mA260 random hexamer
oligonucleotide, 8 mM dithiothreitol (all from Life Technologies), and
0.25 mM each deoxynucleoside triphosphate (Sigma Chemical Co., St.
Louis, Mo.). RT was allowed to proceed for 60 min at 37°C followed by
5 min at 90°C. After the reaction, 175 µl of double-distilled
H2O was added, bringing the total volume to 200 µl, and
the samples were stored at
20°C until used for amplification. A
10-µl volume of cDNA was amplified in a 50-µl reaction volume
containing 0.2 mM each deoxynucleoside triphosphate, 0.2 µM primers,
1 U of Taq polymerase (Life Technologies), and 5 µl of
10× PCR buffer with 1.5 mM MgCl2 (Promega, Madison, Wis.).
The primers used for IL-5 were as follows: 5' primer,
GAC-AAG-CAA-TGA-GAC-ACG-ATG-AGG; 3' primer,
GAA-CTC-TTG-CAG-GTA-ATC-CAG-G. The primer sequences for hypoxanthine
phosphoribosyltransferase (HPRT) were as follows: 5' primer,
GTT-GGA-TAC-AGG-CCA-GAC-TTT-GTT-G; 3' primer,
GAT-TCA-ACT-TGC-GCT-CAT-CTT-AGG-C (14). The primer sequences
for surface antigen 2 (SAG-2) were as follows: 5' primer,
AAC-AGA-AGA-TCT-AAA-ATG-AGT-TTC-TCA-AAG; 3' primer,
GGG-CTA-CAC-AAA-CGT-GAT-CAA-CAA-ACC-TGC. The number of amplification
cycles used was 32, 35, and 23 for IL-5, SAG-2 (p22), and HPRT, respectively.
For Southern blotting, 13.2 µl of PCR product was separated on a 1%
agarose gel. The gel was incubated for 35 min in denaturing
solution
(1.5 M NaCl, 0.5 M NaOH) followed by 30 min in neutralization
solution
(1.5 M NaCl, 1 M Tris-HCl [pH 7.5]). The DNA products
were
transferred by blotting to a nylon membrane (Hybond-N+; Amersham
Life
Science Inc., Arlington Heights, Ill.), and cross-linking
was performed
by UV irradiation (1200 µJ; UV Stratalinker 2400;
Stratagene, La
Jolla, Calif.) and heating for 2 h at 80°C. Immobilized
amplification products were detected by using the enhanced
chemiluminescence
system as specified by manufacturer (Amersham Life
Science Inc.).
Briefly, the membranes were hybridized with fluorescein
isothiocyanate
(FITC)-labeled oligonucleotide probes, incubated with
horseradish
peroxidase (HRP)-conjugated anti-FITC antibody (Ab), and
visualized
with enhanced chemiluminescence detection reagent. The probe
sequences
used were GGG-GGT-ACT-GTG-GAA-ATG-CTA-T for IL-5,
GTT-GTT-GGA-TAT-GCC-CTT-GAC
for HPRT (
14), and
CGA-GGA-AGT-TGA-CGA-CTG-TCC for SAG-2.
Spleen cell culture.
Spleens were collected and placed into
cDMEM, composed of DMEM (Life Technologies) supplemented with 10%
fetal calf serum (Hyclone Laboratories), penicillin (100 U/ml),
streptomycin (100 µg/ml), sodium pyruvate (1 mM), nonessential amino
acid solution (0.1 mM), HEPES buffer (10 mM) (all from Life
Technologies), and
-mercaptoethanol (50 µM) (Sigma Chemical Co.).
After gentle mashing, the resulting single-spleen-cell suspension was
centrifuged for 7 min at 1,000 × g, the supernatant
was decanted, and erythrocytes were lysed by resuspending the cells in
1 ml of erythrocyte lysis buffer (Sigma Chemical Co.) and incubating
them for 30 s. After two washes in cDMEM, the cells were adjusted
to 5 × 106/ml and placed into culture with STAg, and
after 24 or 96 h at 37°C, supernatants were collected for
cytokine measurement.
To remove B lymphocytes from the responder spleen cell population,
monoclonal Ab (MAb)- and complement-mediated depletion
was used, as
previously described (
9). Briefly, a single-cell
suspension
of splenocytes was incubated for 45 min on ice with
medium alone as a
control or with hybridoma supernatant containing
anti-B220 MAb, washed
with cDMEM, and incubated for 45 min with
rabbit serum as a source of
complement (Accurate Chemical & Scientific
Corp., Westbury, N.Y.) at
37°C. This cycle of Ab- plus complement-mediated
depletion was
repeated once. Fluorescence-activated cell sorter
(FACS) analysis
confirmed that 91% of B220
+ cells were depleted compared
to the control group treated with
complement alone. Cells from the
control group were counted and
adjusted to 5 × 10
6
cells/ml, and 200 µl of cell suspension was placed into each
well of
a 96-well plate. To directly compare the cytokine response
in the
presence and absence of B lymphocytes, the B-cell-depleted
population
was adjusted to the same volume as the control group
and 200 µl of
cells was placed into culture. After a 72-h culture
with STAg (100 µg/ml), supernatants were collected for cytokine
measurement. In some
cultures, protein G-purified anti-IL-5 MAb
(TRFK.5) and control rat Ig
was
included.
Cytokine ELISA.
To measure IL-12(p40), cytokine-specific MAb
C15.6 and C17.8, kindly provided by G. Trinchieri, Wistar Institute
(58), were used. To perform the enzyme-linked immunosorbent
assay (ELISA), 96-well plates (Corning Costar Corp., Cambridge, Mass.)
were coated overnight at 4°C with MAb C15.6 in PBS (10 µg/ml) and
then given three washes in PBS containing 0.05% Tween (PBST). The
plates were blocked for 2 h at 37°C in PBS plus 1% bovine serum
albumin (Sigma Chemical Co.), and washed in PBST; then sample
supernatants and IL-12 standard (Genzyme Corp., Cambridge, Mass.) were
added, and the plates were incubated overnight at 4°C. The plates
were washed in PBST, biotinylated MAb C17.8 was added, and the plates were incubated at 37°C for 90 min. HRP-conjugated streptavidin (Genzyme Corp.) was then added, and the plates were incubated for 60 min at 37°C. Finally, 100 µl of
2,2-azinodi(3-ethylbenzthiazoline-6-sulfonate) substrate (ABTS)
(Kirkegaard & Perry Laboratories, Gaithersburg, Md.) was added to each
well, and sample absorbances were measured on a Microplate Bio Kinetics
reader (Bio-Tek Instruments Inc., Winooski, Vt.) at 405 nm.
IFN-

was measured in a similar manner to the IL-12 ELISA, using
plate-bound anti-IFN-

MAb HB170, biotinylated anti-IFN-
MAb
XMG1.2 (Pharmingen Inc., San Diego, Calif.), and HRP-conjugated
streptavidin (Genzyme Corp.). Sample absorbances were measured
at 405 nm following ABTS
addition.
TNF-

levels were measured by a mouse-specific TNF-

ELISA kit as
specified by the manufacturer (Genzyme Corp.).
Antibody ELISA.
Blood was obtained by cardiac puncture with
syringes preloaded with EDTA (Sigma Chemical Co.). Plasma was collected
by centrifugation and stored at
70°C until the day of the assay. We
coated 96-well plates with STAg in PBS (5 µg/ml) by overnight
incubation at 4°C. After blocking at 37°C for 2 h in PBS plus
1% bovine serum albumin, the plates were washed in PBST, serial
dilutions of plasma were added, and the plates were incubated for
2 h at 37°C. After the plates were washed in PBST,
enzyme-conjugated isotype-specific detection Ab were added. To detect
total Ig, an HRP-conjugated goat anti-mouse Ig (Jackson Immunoresearch
Laboratory Inc., West Grove, Pa.) was used. IgG1 was detected with
alkaline phosphatase-conjugated goat anti-mouse IgG1 (Pharmingen Inc.).
HRP-conjugated goat anti-mouse IgG2a (Southern Biotechnology Associates
Inc., Birmingham, Ala.) and HRP-conjugated goat anti-mouse IgM
(Southern Biotechnology Associates Inc.) were used for detection of
IgG2a and IgM, respectively. HRP- or alkaline phosphatase-conjugated
anti-mouse Ab were used at a 1:1,000 dilution (1-h incubation at
37°C). Finally, 100 µl of ABTS substrate (for HRP-conjugated Ab) or
0.05% p-nitrophenyl phosphate (Sigma Chemical Co.) in
diethanolamine buffer (1 M diethanolamine, 0.02% NaN3,
0.01% MgCl2 [pH 9.8]) (for alkaline
phosphatase-conjugated Ab) was added to the plates, and the sample
absorbances were measured at 405 nm.
Flow cytometric analysis.
After removal of erythrocytes with
erythrocyte lysis buffer, spleen cells were washed with FACS buffer
(1% fetal calf serum in PBS, 0.1% NaN3), resuspended in
10% normal mouse serum, and incubated on ice for 15 min. After the
cells were washed with FACS buffer, FITC-conjugated anti-B220 (Caltag
Laboratories, San Francisco, Calif.) and phycoerythrin (PE)-conjugated
anti-CD3, FITC-conjugated anti-NK1.1, FITC-conjugated anti-CD8, and
PE-conjugated anti-CD4 (Pharmingen Inc.) were added, and the cells were
incubated on ice for 30 min. The cells were analyzed on a FACScalibur
flow cytometer, and Cell Quest software (Becton Dickinson
Immunocytometry System, San Jose, Calif.) was used to analyze data.
Statistics.
Statistical analyses were performed by the
Wilcoxon rank sum test for mortality data, two-way analysis of variance
for brain cyst numbers, and Student's t test for percent
weight loss. Comparisons with a probability value of <0.05 were
considered to be significant.
 |
RESULTS |
IL-5 is induced during the normal course of T. gondii
infection.
We infected C57BL/6 mice by i.p. injection of 50 ME49
cysts, a dose and route of infection which allow the animals to survive acute-stage disease and establish a chronic infection. As shown in Fig.
1A, IL-5 gene transcripts were
up-regulated in the brains of infected animals on day 14 of infection.
We similarly found IL-5 up-regulation in the spleens of infected WT
mice (Fig. 1B). As expected, IL-5 KO mice displayed no evidence of this
cytokine. IL-5 up-regulation was also detected later during infection
in the same organs (7 weeks [data not shown]).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 1.
Up-regulation of IL-5 during T. gondii
infection. Male C57BL/6 (WT) or IL-5 / (KO) mice were
infected by i.p. injection with 50 ME49 cysts. Their brains (A) and
spleens (B) were removed 14 day later, and expression of IL-5 gene
transcripts was assessed by RT-PCR analysis as described in Materials
and Methods. In this figure, each band represents a single mouse. This
experiment was repeated twice with the same results.
|
|
Because T lymphocytes are regarded as a major source of IL-5 (
4,
22,
30,
34), we infected RAG-1
/
mice with ME49
and asked whether induction of this cytokine continued
to occur. RAG-1
KO animals are unable to use V,D,J recombination
during lymphocyte
ontogeny and, as a result, fail to generate
functional T or B cells
(
33). Nevertheless, IL-5 induction continues
to occur in the
brains and spleens of ME49 infected animals (Fig.
2). Flow cytometric analysis confirmed
that the infected RAG-1
KO mice did not possess any peripheral T or B
lymphocytes (data
not shown). We conclude that IL-5 production during
infection
is not absolutely dependent upon T or B lymphocytes.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
Expression of IL-5 during T. gondii infection
occurs independently of T and B lymphocytes. Female WT (C57BL/6) and
RAG-1 / mice were infected i.p. with 50 ME49 cysts, and
on the indicated days postinfection, brains (A) and spleens (B) were
removed and IL-5 gene expression was assessed by RT-PCR analysis. Each
band represents a single animal. This experiment was performed twice
with the same result.
|
|
IL-5 KO mice display increased susceptibility to T. gondii infection.
IL-5
/
and WT mice were
infected with ME49 to determine the relative ability of the KO strain
to resist infection. Figure 3A shows that
the KO strain displays increased susceptibility. Thus, by week 19 to 20 after infection, 100% of the IL-5
/
but only 40 to 50%
of the WT animals had succumbed.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
IL-5 KO mice display increased mortality and weight loss
during T. gondii infection. (A) Male mice (n = 10 per strain) were infected i.p. with 50 ME49 cysts, and
long-term survival was monitored. The statistical significance of these
results was determined by the generalized Wilcoxon rank sum test
(P = 0.003). (B) The average weight of animals as a
percentage of the starting weight during infection is shown
(n = 14 per strain). The statistical significance of
these results was evaluated by Student's t test
(P < 0.001). Solid circles, WT animals; open circles,
IL-5 KO animals. This experiment was repeated four times with
essentially identical results.
|
|
Although the animals did not begin to die until well into the chronic
stage, the increased susceptibility of the KO strain
was traceable to
earlier times of infection. As shown in Fig.
3B, on day 14 after
infection, IL-5
/
and WT animals had lost 23 and only
13% of their body weight,
respectively. While WT mice began to regain
weight as they proceeded
into the chronic stage, this did not occur in
the KO animals.
Thus, by days 30 to 40 postinfection, the average
weight of the
IL-5
/
mice was 68 to 78% of their
original weight while that of the
WT animals was restored to 87 to 92%
of their original
weight.
Increased parasite levels are associated with IL-5 KO animals.
We next asked whether cyst numbers in WT and KO mice differed. As shown
in Fig. 4, which displays the results of
three experiments, the brains of infected IL-5
/
mice
harbored significantly (P = 0.013) greater cyst numbers than did the brains of WT mice during chronic infection. The increased parasite burden was also evident during examination of levels of mRNA
for the tachyzoite-specific Ag, p22 (SAG-2). Thus, 7 weeks after
infection, a time when the IL-5
/
mice began to die, the
p22 mRNA levels were dramatically elevated relative to those in
infected C57BL/6 animals (Fig. 5).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 4.
IL-5 / mice display increased numbers of
brain cysts relative to WT animals. Groups of male mice (four or five
mice per strain) were infected i.p. with ME49 (experiment 1, 20 cysts;
experiment 2, 50 cysts; experiment 3, 200 cysts), and 1 month later
their brains were removed and the cysts were enumerated. In this
figure, each circle represents a single mouse and the horizontal line
indicates the average cyst number in each group. The results were
analyzed by two-way analysis of variance and found to be statistically
significant (P = 0.012).
|
|

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 5.
Levels of tachyzoite-specific SAG-2 gene transcripts in
the brain are elevated in IL-5 KO animals. Female mice were infected
with 50 ME49 cysts, and 7 weeks later their brains removed and the
levels of SAG-2 gene transcripts were determined by RT-PCR analysis.
Each band in this figure represents the result from a single animal.
This experiment was repeated twice with essentially identical
results.
|
|
Ab isotype profile of infected mice.
IL-5
/
and
WT control mice were bled 7 weeks after infection, and
anti-Toxoplasma Ab titers in serum were determined. The
levels of total parasite-specific Ig, IgM, and IgG2a were comparable in
both mouse strains (Fig. 6).
Nevertheless, T. gondii-specific IgG1 was almost totally
absent in IL-5 KO mice, consistent with previous reports which indicate
that IL-5 enhances IL-4-directed isotype switching to IgG1 secretion
(38, 39). In addition, the relatively low IgG1 titer in WT
mice (approximately 1/200) compared to the IgG2a titer (approximately
1/1,600) is consistent with the known ability of T. gondii
to preferentially induce a strong type 1 cytokine response.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 6.
Parasite-specific Ab levels in plasma in infected WT and
KO mice. Seven weeks following i.p. infection with 50 ME49 cysts,
female animals (n = 4 per strain) were bled and assayed
for T. gondii-specific Ig by isotype-specific ELISA as
described in Materials and Methods. Solid circles, WT mice; open
circles, IL-5 KO animals. These results were also obtained in two
additional repeat experiments.
|
|
Cytokine profile of infected mice.
Spleen cells from
8-week-infected IL-5
/
and control mice were isolated
and incubated with STAg to examine cytokine production in vitro. We
measured production at 24 and 96 h after culture initiation.
IL-5-deficient and normal mice produced similar amounts of TNF-
and
IFN-
24 h after culture initiation, while IL-12 levels were
slightly elevated in WT mice at this time point (Fig. 7). Although TNF-
and IFN-
levels
remained comparable for both strains after 96 h of culture, the
level of IL-12 produced by WT mice was dramatically elevated relative
to that produced by the KO strain at the same time and to the cytokine
levels in WT mice at 24 h. Thus, while production of IL-12 in the
24-h cultures was similar or identical, by 96 h the values had
diverged dramatically as a result of increased WT IL-12 production.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 7.
Spleen cells from IL-5 KO mice display a specific defect
in T. gondii-induced IL-12 production in vitro. At 9 weeks
after ME49 infection, spleen cells from WT and KO animals (n = 4 per group) were isolated and stimulated in vitro with STAg (50 µg/ml). At 24 and 96 h after culture initiation, supernatants
were collected and assayed for the indicated cytokines by ELISA (see
Materials and Methods for details). Solid circles, WT mice; open
circles, KO mice. This experiment was repeated three times with the
same result.
|
|
Phenotypic analysis of spleen cell populations before and after
STAg stimulation.
Since control mice produced larger amounts of
IL-12 during culture with STAg then did KO mice, we determined if the
splenocyte populations in the two strains differed prior to culture
initiation. As shown in Table 1, there
was no difference between the KO and WT strains in terms of spleen cell
populations either before or after infection. In both strains, there
was a decrease in the number of CD4+ cells, while other
cell types remained approximately equivalent.
We next asked if spleen cell populations in WT and KO mice differed
after in vitro stimulation with STAg. At the start of
the experiment,
CD3
+ and B220
+ populations were similar for
both infected strains (Fig.
8A).
We
initiated spleen cell cultures from infected WT and KO mice
in the
presence of STAg or medium (Fig.
8B). At 24 and 48 h after
culture
initiation, cells were harvested and subjected to single-color
FACS
staining with anti-B220 MAb. While B-cell levels in both
strains were
equivalent after 24 h, by 48 h there was a major
decrease in
the B220
+-cell population of the KO strain. Thus, between
24 and 48 h,
the B220
+-cell percentage in the KO
strain decreased from 46 to 8% of the
total STAg-stimulated spleen
population. In contrast, the loss
of B220
+ cells in WT
animals was much less dramatic under the same conditions,
decreasing
from 57 to 48% of the population.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 8.
Loss of B220+ cells in IL-5 /
animals upon in vitro STAg stimulation. At 5 weeks after ME49
infection, spleens from WT and KO mice (n = 4 mice per
group) were isolated. Cells from each strain were pooled and stimulated
in vitro with STAg (50 µg/ml). (A) Cell populations stained with a
combination of PE-conjugated anti-CD3 and FITC-conjugated anti-B220 at
the initiation of cell culture. (B and C) At 24 and 48 h after
culture with medium or STAg, cells were harvested and stained with
FITC-conjugated anti-B220 (B) or with a combination of FITC-conjugated
anti-CD8 and PE-conjugated anti-CD4 (C). This experiment was repeated
twice with essentially identical results.
|
|
Figure
8C demonstrates that the loss of B cells in cultures of
STAg-stimulated IL-5
/
splenocytes was a specific B-cell
effect and that it was not
due to increased death in the KO population
as a whole. Thus,
between 24 and 48 h of culture with STAg, the
percentage of T
cells increased (CD4
+ increased from 19 to
38%, and CD8
+ increased from 25 to 44%) in the KO strain
while T-cell levels
in the WT strain remained approximately equivalent.
The proportional
increase in the T-cell percentage is consistent with a
specific
B-cell loss (Fig.
8B) in the STAg-stimulated splenocytes from
KO mice. Indeed, in terms of absolute number, both strains contain
similar numbers of CD4
+ and CD8
+ cells, while
the B220
+-cell number in the KO strain decreased (data not
shown), again
arguing for selective B-cell loss rather than increased
T-cell
proliferation in the spleen cells from KO
mice.
Decreased IL-12 production is associated with B-cell loss.
Since lower levels of IL-12 in the cultures of cells from KO mice were
associated with selective B-lymphocyte loss in the same culture, this
suggested that B cells may normally contribute to IL-12 production in
STAg-stimulated cultures. To address this issue, we used anti-B220 MAb
and complement to deplete splenocyte populations of B cells in KO and
WT mice and examined the ability of the remaining cells to produce
IL-12 in response to STAg. As shown in Fig.
9A, the intact splenocyte population in
WT mice produced nearly twice the amount of IL-12 as did the
splenocytes in KO mice in response to STAg stimulation. However, in the
absence of B cells, both strains produced equivalent amounts of IL-12. These results suggest that B cells in the cultures of cells from WT
mice promote STAg-induced IL-12 and that in the cultures of cells from
KO mice, where the cells do not persist, their contribution is
correspondingly reduced.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 9.
STAg-induced IL-12 production in vitro is partially
inhibited by depletion of B220+ cells and IL-5. (A) At 5 weeks after ME49 infection, spleen cells from three WT (shaded bars)
and three KO (open bars) mice were collected and pooled, and half of
the population was B-cell depleted with anti-B220 MAb and complement
while the other half was treated with complement alone. The resulting
cells were cultured with STAg (100 µg/ml), and after 72 h the
supernatants were harvested and the IL-12 level was measured. (B)
Spleen cells from chronically infected WT mice were cultured with the
indicated doses of STAg in the presence of 20 µg of TRFK.5 (anti-IL-5
MAb) per ml or the same concentration of control rat Ig. After 96 h, supernatants were harvested and the level of IL-12 was measured.
This experiment was repeated twice with essentially identical
results.
|
|
We also directly examined whether IL-5 was involved in IL-12 production
in cultures of parasite-stimulated spleen cells. As
shown in Fig.
9B,
addition of anti-IL-5 MAb TRFK.5 resulted in
a decrease in IL-12
production of approximately 50% relative to
that in cultures in the
presence of control rat
Ig.
 |
DISCUSSION |
The type 2 cytokine IL-5 is conventionally associated with
helminth infection and allergy (25, 27, 30, 53), and control of intracellular pathogens such as T. gondii is largely
controlled by the type 1 cytokines IL-12, TNF-
, and IFN-
(1,
8, 10, 13, 43). Nevertheless, our results demonstrate that mice
deficient for IL-5 production displayed increased susceptibility to the parasite, as measured by accelerated mortality, elevated parasite numbers within the brain, and increased weight loss during acute infection. These results therefore establish a protective role for IL-5
during T. gondii infection.
Although T. gondii is well known as a potent stimulator of
type 1 cytokines, overproduction of the same cytokines can be
detrimental to the host. However, it is now clear that type 2 cytokine
production also is an important component of the host response to this
opportunistic pathogen. Thus, mice deficient in IL-10 production
display increased mortality, which appears to result from a
dysregulated inflammatory cytokine response rather than to an inability
to control the parasite (15, 35). The role of IL-4 during
T. gondii infection is less clear, although IL-4 KO animals
also display increased mortality (41, 48).
Employing RT-PCR-based analysis, we found that IL-5 transcripts were
induced in spleens and brains during both the acute stage (days 12 and
14 postinfection) and the chronic stage (7 weeks postinfection). Our
data are consistent with previous results, which showed IL-5 mRNA
induction in brains and spleens of mice 14 and 90 days after
inoculation with the ME49 strain (2). A similar study showed
that mesenteric lymph node cells from infected mice produced IL-5 when
restimulated in vitro with toxoplasma sonicate as well as with purified
T. gondii Ag (6).
Activated CD4+ T cells are regarded as the main source of
IL-5 (4, 22, 30, 34), but other subpopulations of T cells, including CD3+ 
TCR+ T cells in the
intestinal mucosa and peripheral CD8+ T cells, can also
produce this cytokine (5, 50). In addition, non-T-cell IL-5
sources have been identified, including natural killer cells (53,
54), mast cells (55), Epstein-Barr virus-transformed B
cells (24), and eosinophils (3, 11). In the
present study, IL-5 mRNA was induced in T. gondii-infected
RAG-1
/
mice. Thus, our results strongly suggested that
the source of IL-5 in the brains and spleens of infected mice is
neither T- nor B-cell derived and that the induction of this cytokine
is T- and B-cell independent.
Since IL-5 has effects on B cells and is capable of influencing the Ab
isotype repertoire, we compared the plasma Ab response of infected WT
and KO animals. The production of parasite-specific total Ig, IgM, and
IgG2a was comparable, and the production of IgE was undetectable in
both strains. However, T. gondii-specific IgG1 was
undetectable in IL-5 KO mice. Our results are consistent with previous
reports which suggest that although IL-4 is the critical cytokine in
IgG1 isotype switching, B cells require a second signal, provided by
IL-5, to secrete this antibody isotype (37-39).
In this study, we used flow cytometry to analyze splenocyte populations
and found that the percentage of B and T cells in both strains was
comparable in uninfected control and T. gondii-infected mice. When spleen cells from the infected mice were cultured with STAg,
there was a selective loss of B220+ cells from the KO
strain between 24 and 48 h of culture. At least two possible
explanations may account for this. First, in addition to promoting
differentiation, IL-5 can promote B-cell proliferation (49, 51,
52). Therefore, it is possible that during STAg restimulation,
IL-5 normally acts as a helper factor which serves to sustain B-cell
proliferation during extended culture. Second, IL-5 is well known to
possess antiapoptotic effects. Thus, the cytokine up-regulates Bcl-2
expression in eosinophils, rendering the cells resistant to inducers of
apoptosis (36, 47). In addition, IL-5 blocks
anti-IgM-induced apoptosis of immature B-cell lines (21).
Therefore, it is possible that IL-5 normally exerts antiapoptotic
effects on the B cells present in STAg-stimulated splenocyte
populations. We are currently exploring the mechanisms underlying the
selective B-cell loss in cell cultures derived from the KO animals.
Of interest is the profile of cytokine production in STAg-stimulated
spleen cell cultures. We measured IL-12, IFN-
, and TNF-
production at 24 and 96 h after culture initiation and found that the amounts of IFN-
and TNF-
were essentially the same in
IL-5
/
and WT animals. However, although both mouse
strains produced a comparable amount of IL-12 at 24 h, cells from
WT mice produced more IL-12 after 96 h of culture than did cells
from the KO strain. Because the divergence of IL-12 production between
the two strains generally correlated with the loss of B cells in the KO
strain, our results suggest that decreasing B-lymphocyte numbers
account for the lower level of IL-12 in the KO strain. Support for this hypothesis comes from our finding that in the absence of B lymphocytes, both KO and WT strains produced a similar amount of IL-12 in response to STAg.
Our results clearly link B-cell loss to lower IL-12 production in
cultures of STAg-stimulated splenocytes, but we do not yet understand
the mechanism by which this occurs. One possibility is that B cells
themselves serve as an IL-12 source in the extended cultures. While
IL-12 was originally isolated from a transformed B-cell line
(24), it is a matter of controversy whether normal B cells
produce IL-12, with evidence both for (7, 45) and against
(18, 42).
A second possibility is that B lymphocytes are indirectly involved in
IL-12 production, possibly through CD40-CD40 ligand (CD40L)-dependent
triggering. In this regard, macrophage and dendritic cells can produce
IL-12 through CD40-CD40L interaction (17, 23, 46).
Expression of the CD40L on T cells is inducible by activated B cells
and can be stabilized by B7/CD28 costimulation (19, 20).
Furthermore, B cells themselves are able to express the CD40L under
certain conditions (16, 44, 56). Therefore, it is possible
that in the splenocyte cultures from WT mice, B cells augment IL-12
production by promoting CD40-CD40L interactions and that the selective
B-cell loss in cultures of cells from IL-5
/
mice
results in decreased IL-12 production. We are currently directing our
efforts to resolving these issues.
We do not know why the IL-5 KO mice display greater susceptibility to
T. gondii infection. While splenocytes from these mice clearly produce less IL-12 upon in vitro stimulation, we do not know
whether this is a true reflection of the in vivo situation and, if so,
whether lower in vivo IL-12 levels result in increased susceptibility
to the parasite. We also found that the KO mice produce very little
parasite-specific IgG1 after infection. Although it is formally
possible that this impairs the ability to survive infection, we think
this unlikely, since Ab in general are not believed to be required for
resistance to the parasite (12, 40). Regardless of the
reason for the death of these animals, our results reveal an unexpected
link between endogenous IL-5 production and B-cell-dependent IL-12
production. Uncovering the mechanism underlying this unique observation
may provide further insight into the mechanisms of immunity to T. gondii and other microbial pathogens.
 |
ACKNOWLEDGMENT |
We thank Susan Bliss for critical review and useful discussion.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853. Phone: (607) 253-4022. Fax: (607) 253-3384. E-mail: eyd1{at}cornell.edu.
Editor:
J. M. Mansfield
 |
REFERENCES |
| 1.
|
Alexander, J., and C. A. Hunter.
1998.
Immunoregulation during toxoplasmosis.
Chem. Immunol.
70:81-102[Medline].
|
| 2.
|
Arsenijevic, D.,
L. Girardier,
J. Seydoux,
H. R. Chang, and A. G. Dulloo.
1997.
Altered energy balance and cytokine gene expression in a murine model of chronic infection with Toxoplasma gondii.
Am. J. Physiol.
272:E908-E917[Abstract/Free Full Text].
|
| 3.
|
Bao, S.,
S. J. McClure,
D. L. Emery, and A. J. Husband.
1996.
Interleukin-5 mRNA expressed by eosinophils and gamma/delta T cells in parasite-immune sheep.
Eur. J. Immunol.
26:552-556[Medline].
|
| 4.
|
Bohjanen, P. R.,
M. Okajima, and R. J. Hodes.
1990.
Differential regulation of interleukin 4 and interleukin 5 gene expression: a comparison of T-cell gene induction by anti-CD3 antibody or by exogenous lymphokines.
Proc. Natl. Acad. Sci. USA
87:5283-5287[Abstract/Free Full Text].
|
| 5.
|
Cardell, S.,
B. Sander, and G. Moller.
1991.
Helper interleukins are produced by both CD4 and CD8 splenic T cells after mitogen stimulation.
Eur. J. Immunol.
21:2495-2500[Medline].
|
| 6.
|
Chardes, T.,
F. Velge-Roussel,
M.-N. Mevelec,
P. Mevelec,
D. Buzoni-Gatel, and D. Bout.
1993.
Mucosal and systemic cellular immune responses induced by Toxoplasma gondii antigens in cyst orally infected mice.
Immunology
78:421-429[Medline].
|
| 7.
|
D'Andrea, A. M.,
M. Rengarajau,
N. Valiante,
J. Chemini,
M. Kubin,
M. Aste-Amezaga,
S. H. Chan,
M. Kobayashi,
D. Young,
R. Nickbarg,
R. Chizzonite,
S. F. Wolf, and G. Trinchieri.
1992.
Production of natural killer cell stimulatory factor (NKSF/IL-12) by peripheral blood mononuclear cells.
J. Exp. Med.
176:1387-1397[Abstract/Free Full Text].
|
| 8.
|
Denkers, E. Y., and R. T. Gazzinelli.
1998.
Regulation and function of T cell-mediated immunity during Toxoplasma gondii infection.
Clin. Microbiol. Rev.
11:569-588[Abstract/Free Full Text].
|
| 9.
|
Denkers, E. Y.,
R. T. Gazzinelli,
D. Martin, and A. Sher.
1993.
Emergence of NK1.1+ cells as effectors of immunity to Toxoplasma gondii in MHC class I-deficient mice.
J. Exp. Med.
178:1465-1472[Abstract/Free Full Text].
|
| 10.
|
Denkers, E. Y.,
T. Scharton-Kersten,
R. T. Gazzinelli,
G. Yap,
H. Charest, and A. Sher.
1997.
Cell-mediated immunity to Toxoplasma gondii: redundant and required mechanisms as revealed by studies in gene knockout mice, p. 167-181.
In
S. H. E. Kaufmann (ed.), Medical intelligence unit: host response to intracellular pathogens. R. G. Landes Co., Austin, Tex.
|
| 11.
|
Desreumaux, P.,
E. Delaporte,
J. F. Clombel,
M. Capron,
A. Cortot, and A. Janin.
1998.
Similar IL-5, IL-3, and GM-CSF syntheses by eosinophils in the jejunal mucosa of patients with celiac disease and dermatitis herpetiformis.
Clin. Immunol. Immunopathol.
88:14-21[Medline].
|
| 12.
|
Frenkel, J. K.
1967.
Adoptive immunity to intracellular infection.
J. Immunol.
98:1309-1319[Abstract/Free Full Text].
|
| 13.
|
Gazzinelli, R. T.,
E. Y. Denkers, and A. Sher.
1993.
Host resistance to Toxoplasma gondii: model for studying the selective induction of cell-mediated immunity by intracellular parasites.
Infect. Agents Dis.
2:139-149[Medline].
|
| 14.
|
Gazzinelli, R. T.,
S. Hieny,
T. Wynn,
S. Wolf, and A. Sher.
1993.
IL-12 is required for the T-cell independent induction of IFN- by an intracellular parasite and induces resistance in T-cell-deficient hosts.
Proc. Natl. Acad. Sci. USA
90:6115-6119[Abstract/Free Full Text].
|
| 15.
|
Gazzinelli, R. T.,
M. Wysocka,
S. Hieny,
T. Scharton-Kersten,
A. Cheever,
R. Kuhn,
W. Muller,
G. Trinchieri, and A. Sher.
1996.
In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent upon CD4+ T cells and accompanied by overproduction of IL-12, IFN- , and TNF- .
J. Immunol.
157:798-805[Abstract].
|
| 16.
|
Grammar, A. C.,
M. C. Bergman,
Y. Miura,
K. Fujita,
L. S. Davis, and P. E. Lipsky.
1995.
The CD40 ligand expressed by human B cells costimulates B cell responses.
J. Immunol.
154:4996-5010[Abstract].
|
| 17.
|
Grewal, I. S., and R. A. Flavell.
1996.
The role of CD40 ligand in costimulation and T-cell activation.
Immunol. Rev.
153:85-106[Medline].
|
| 18.
|
Guery, J. C.,
F. Ria,
F. Galbiati, and L. Adorini.
1997.
Normal B cells fail to secrete interleukin-12.
Eur. J. Immunol.
27:1632-1639[Medline].
|
| 19.
|
Jaiswal, A. I., and M. Croft.
1997.
CD40 ligand induction on T cell subsets by peptide-presenting B cells: implications for development of the primary T and B cell response.
J. Immunol.
159:2282-2291[Abstract/Free Full Text].
|
| 20.
|
Johnson-Leger, C.,
J. Christensen, and G. G. Klaus.
1998.
CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells.
Int. Immunol.
10:1083-1091[Abstract/Free Full Text].
|
| 21.
|
Kamesaki, H.,
J. A. Zwiebel,
J. C. Reed, and J. Cossman.
1994.
Role of bcl-2 and IL-5 in the regulation of anti-IgM-induced growth arrest and apoptosis in immature B cell lines. A cooperative regulation model for B cell clonal deletion.
J. Immunol.
152:3294-3305[Abstract].
|
| 22.
|
Karlen, S.,
M. L. De Boer,
R. J. Lipscombe,
W. Lutz,
V. A. Mordvinov, and C. J. Sanderson.
1998.
Biological and molecular characteristics of interleukin-5 and its receptor.
Int. Rev. Immunol.
16:227-247[Medline].
|
| 23.
|
Kehry, M. R., and P. D. Hodgkin.
1993.
Helper T cells: delivery of cell contact and lymphokine-dependent signals to B cells.
Semin. Immunol.
5:393-400[Medline].
|
| 24.
|
Kobayashi, M.,
L. Fitz,
M. Ryan,
R. M. Hewik,
S. C. Clark,
S. Chan,
R. Louden,
F. Sherman,
B. Perussia, and G. Trinchieri.
1989.
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes.
J. Exp. Med.
170:827-845[Abstract/Free Full Text].
|
| 25.
|
Koike, M., and K. Takatsu.
1994.
IL-5 and its receptor: which role do they play in the immune response?
Int. Arch. Allergy Immunol.
104:1-9[Medline].
|
| 26.
|
Kopf, M.,
F. Brombacher,
P. D. Hodgkin,
A. J. Ramsay,
E. A. Milbourne,
W. J. Dai,
K. S. Ovington,
C. A. Behm,
G. Kohler,
I. G. Young, and K. I. Matthaei.
1996.
IL-5 deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.
Immunity
4:15-24[Medline].
|
| 27.
|
Kotsimbos, A. T. C., and Q. Hamid.
1997.
IL-5 and IL-5 receptor in asthma.
Mem. Inst. Oswaldo Cruz
92:75-91.
|
| 28.
|
Krahenbul, J. L., and J. S. Remington.
1982.
Immunology of toxoplasma and toxoplasmosis, p. 356-421.
In
S. Cohen, and K. S. Warren (ed.), Immunology of parasitic infections. Blackwell Scientific Publications, London, United Kingdom.
|
| 29.
|
Luft, B. J., and J. S. Remington.
1992.
Toxoplasmic encephalitis in AIDS.
Clin. Infect. Dis.
15:211-222[Medline].
|
| 30.
|
Mahanty, S., and T. Nutman.
1993.
The biology of interleukin-5 and its receptor.
Cancer Investig.
11:624-634[Medline].
|
| 31.
|
Marshall, A. J., and E. Y. Denkers.
1998.
Toxoplasma gondii triggers granulocyte-dependent, cytokine-mediated lethal shock in D-galactosamine sensitized mice.
Infect. Immun.
66:1325-1333[Abstract/Free Full Text].
|
| 32.
|
McCabe, R., and J. S. Remington.
1988.
Toxoplasmosis: the time has come.
N. Eng. J. Med.
380:313-315.
|
| 33.
|
Mombaerts, P.,
J. Iacomini,
R. S. Johnson,
K. Herrup,
S. Tonegawa, and V. E. Papaionnou.
1992.
RAG-1-deficient mice have no mature B and T lymphocytes.
Cell
68:869-877[Medline].
|
| 34.
|
Naora, H.,
J. G. Altin, and I. G. Young.
1994.
TCR-dependent and -independent signaling mechanisms differentially regulate lymphokine gene expression in the murine T helper clone D10.G4.1.
J. Immunol.
152:5691-5702[Abstract].
|
| 35.
|
Neyer, L. E.,
G. Grunig,
M. Fort,
J. S. Remington,
D. Rennick, and C. A. Hunter.
1997.
Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii.
Infect. Immun.
65:1675-1682[Abstract].
|
| 36.
|
Ochiai, K.,
M. Kagami,
R. Matumura, and H. Tomioka.
1997.
IL-5 but not interferon-gamma (IFN- ) inhibit eosinophil apoptosis by up-regulation of bcl-2 expression.
Clin. Exp. Immunol.
107:198-204[Medline].
|
| 37.
|
Parker, S. J.,
C. W. Roberts, and J. Alexander.
1991.
CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice.
Clin. Exp. Immunol.
84:207-212[Medline].
|
| 38.
|
Purkerson, J. M., and P. C. Isakson.
1992.
Interleukin 5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE.
J. Exp. Med.
175:973-982[Abstract/Free Full Text].
|
| 39.
|
Purkerson, J. M., and P. C. Isakson.
1992.
A two-signal model for regulation of immunoglobulin isotype switching.
FASEB J.
6:3245-3252[Abstract].
|
| 40.
|
Reyes, L., and J. K. Frenkel.
1987.
Specific and nonspecific mediation of protective immunity to Toxoplasma gondii.
Infect. Immun.
55:856-863[Abstract/Free Full Text].
|
| 41.
|
Roberts, C. W.,
D. J. P. Ferguson,
H. Jebbari,
A. Satoskar,
H. Bluethmann, and J. Alexander.
1996.
Different roles for interleukin-4 during the course of Toxoplasma gondii infection.
Infect. Immun.
64:897-904[Abstract].
|
| 42.
|
Sartori, A.,
X. Ma,
G. Gri,
L. Showe,
D. Benjamin, and G. Trinchieri.
1997.
Interleukin-12: an immunoregulatory cytokine produced by B cells and antigen-presenting cells.
Methods
11:116-127[Medline].
|
| 43.
|
Scharton-Kersten, T.,
E. Y. Denkers,
R. T. Gazzinelli, and A. Sher.
1995.
Role of IL-12 in the induction of cell-mediated immunity to Toxoplasma gondii.
Res. Immunol.
146:539-545[Medline].
|
| 44.
|
Schattner, E. J.,
J. Mascarenhas,
I. Reyfman,
M. Koshy,
C. Woo,
S. M. Friedman, and M. K. Crow.
1998.
Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity.
Blood
91:2689-2697[Abstract/Free Full Text].
|
| 45.
|
Schultze, J. L.,
S. Michalak,
J. Lowne,
A. Wong,
M. H. Gilleece,
J. G. Gribben, and L. M. Nadler.
1998.
Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses.
J. Exp. Med.
189:1-12[Abstract/Free Full Text].
|
| 46.
|
Shu, U.,
M. Kiniwa,
C. Y. Wu,
C. Malizewski,
N. Vezzio,
J. Hakimi,
M. Gately, and G. Delespesse.
1995.
Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction.
Eur. J. Immunol.
25:1125-1128[Medline].
|
| 47.
|
Stern, M.,
L. Meagher,
J. Savill, and C. Haslett.
1992.
Apoptosis in human eosinophils programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5.
J. Immunol.
148:3543-3549[Abstract].
|
| 48.
|
Suzuki, Y.,
Q. Yang,
S. Yang,
N. Nguuyen,
S. Lim,
O. Leisenfeld,
T. Kojima, and J. Remington.
1996.
IL-4 is protective against development of toxoplasmic encephalitis.
J. Immunol.
157:2564-2569[Abstract].
|
| 49.
|
Swain, S. L.,
D. T. McKenzie,
R. W. Dutton,
S. L. Tonkonogy, and M. English.
1988.
The role of IL4 and IL5: characterization of a distinct helper T cell subset that makes IL4 and IL5 (Th 2) and requires priming before induction of lymphokine secretion.
Immunol. Rev.
102:77-105[Medline].
|
| 50.
|
Taguchi, T.,
W. K. Aicher,
K. Fujihashi,
M. Yamamoto,
J. R. McGhee,
J. A. Bluestone, and H. Kiyono.
1991.
Novel function for intestinal intraepithelial lymphocytes, Murien CD3+ gamma/delta TCR+ T cells produce IFN-gamma and IL-5.
J. Immunol.
147:3736-3744[Abstract].
|
| 51.
|
Takatsu, K.,
A. Tominage,
N. Harada,
S. Mita,
M. Matsumoto,
T. Takahashi,
Y. Kikuchi, and N. Yamaguchi.
1988.
T cell-replacing factor (TRF)/interleukin 5 (IL-5): molecular and functional properties.
Immunol. Rev.
102:107-135[Medline].
|
| 52.
|
Vitetta, E. S.,
K. Brooks,
Y. W. Chen,
P. Isakson,
S. Jones,
J. Layton,
G. C. Mishra,
E. Pure,
E. Weiss,
E. Word,
D. Yuan,
P. Tucker,
J. W. Uhr, and P. H. Krammer.
1988.
T cell derived lymphokines that induce IgM and IgG secretion in activated murine B cells.
Immunol. Rev.
78:137-157.
|
| 53.
|
Walker, C.,
J. Checkel,
S. Cammisuli,
P. J. Leibson, and G. J. Gleich.
1998.
IL-5 production by NK cells contributes to eosinophil infiltration in a mouse model of allergic inflammation.
J. Immunol.
161:1962-1969[Abstract/Free Full Text].
|
| 54.
|
Warren, H. S.,
B. F. Kinnear,
J. H. Phillips, and L. L. Lanier.
1995.
Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12.
J. Immunol.
154:5144-5152[Abstract].
|
| 55.
|
Williams, C. M., and J. W. Coleman.
1995.
Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A.
Immunology
86:244-249[Medline].
|
| 56.
|
Wykes, M.,
J. Poudrier,
R. Lindstedt, and D. Gray.
1998.
Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells.
Eur. J. Immunol.
28:548-559[Medline].
|
| 57.
|
Wynn, T. A.,
I. Eltoum,
A. W. Cheever,
F. A. Lewis,
W. C. Gause, and A. Sher.
1993.
Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni.
J. Immunol.
151:1430-1440[Abstract].
|
| 58.
|
Wysocka, M.,
M. Kubin,
L. Q. Vieira,
L. Ozmen,
G. Garotta,
P. Scott, and G. Trinchieri.
1995.
Interleukin-12 is required for interferon- production and lethality in lipopolysaccharide-induced shock in mice.
Eur. J. Immunol.
25:672-676[Medline].
|
Infection and Immunity, September 1999, p. 4383-4392, Vol. 67, No. 9
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Liesenfeld, O., Dunay, I. R., Erb, K. J.
(2004). Infection with Toxoplasma gondii Reduces Established and Developing Th2 Responses Induced by Nippostrongylus brasiliensis Infection. Infect. Immun.
72: 3812-3822
[Abstract]
[Full Text]
-
Nickdel, M. B., Roberts, F., Brombacher, F., Alexander, J., Roberts, C. W.
(2001). Counter-Protective Role for Interleukin-5 during Acute Toxoplasma gondii Infection. Infect. Immun.
69: 1044-1052
[Abstract]
[Full Text]
-
Le Goff, L., Loke, P'n., Ali, H. F., Taylor, D. W., Allen, J. E.
(2000). Interleukin-5 Is Essential for Vaccine-Mediated Immunity but Not Innate Resistance to a Filarial Parasite. Infect. Immun.
68: 2513-2517
[Abstract]
[Full Text]